The authors declare a conflict of interest. Outside the submitted work, D.R.G. reports
an unconditional grant from Correvio Italia, and investigator-initiated grants from
Pfizer Inc and Gilead Italia. J.P. has received personal fees from Gilead Sciences
and Pfizer, research funding from MSD outside of the submitted work and is stakeholder
of AbbVie and Novo Nordisk. J.W. reports grants and personal fees from Gilead and
Pfizer: investigator-initiated grants, personal fees and also non-financial support
from MSD, outside the submitted work. J.M. reports grants, personal fees and non-financial
support from MSD, grants, personal fees and non-financial support from Pfizer Inc.,
grants, personal fees and non-financial support from Gilead Sciences, personal fees
and non-financial support from Astellas Pharma, personal fees and non-financial support
from Cidara, personal fees and non-financial support from F2G, personal fees and non-financial
support from Mundipharma, personal fees and non-financial support from Takeda/Shire,
outside of the submitted work. O.A.C reports grants or contracts from Amplyx, Basilea,
BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma,
Octapharma, Pfizer, Scynexis; Consulting fees from Amplyx, Biocon, Biosys, Cidara,
Da Volterra, Gilead, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon,
Octapharma, PSI, Scynexis, Seres; Honoraria for lectures from Abbott, Al-Jazeera Pharmaceuticals,
Astellas, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD,
Mylan, Pfizer; Payment for expert testimony from Cidara; Participation on a Data Safety
Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA,
Jannsen, MedPace, Paratek, PSI, Shionogi; A pending patent currently reviewed at the
German Patent and Trade Mark Office; Other interests from DGHO, DGI, ECMM, ISHAM,
MSG-ERC, Wiley, outside the submitted work. J.S.-G. has received lecture honoraria
from Gilead and Pfizer, outside the submitted work. M. Bassetti has received funding
for scientific advisory boards, travel and speaker honoraria from Angelini, Astellas,
Bayer, BioMèrieux, Cidara, Cipla, Gilead, Menarini, MSD, Pfizer and Shionogi. R.R.-R.
has received speaker honoraria from Astellas Pharma, Gilead Sciences, Pfizer, and
research funding from Associates of Cape Cod. P.K. reports grants or contracts from
German Federal Ministry of Research and Education and the State of North Rhine-Westphalia;
Consulting fees Ambu GmbH, Gilead Sciences, Noxxon N.V. and Pfizer Pharma; Honoraria
for lectures from Akademie für Infektionsmedizin e.V., Ambu GmbH, Astellas Pharma,
BioRad Laboratories Inc., European Confederation of Medical Mycology, Gilead Sciences,
GPR Academy Ruesselsheim, medupdate GmbH, MedMedia, MSD Sharp & Dohme GmbH, Pfizer
Pharma GmbH, Scilink Comunicación Científica SC and University Hospital and LMU Munich;
Participation on an Advisory Board from Ambu GmbH, Gilead Sciences, Pfizer Pharma;
A pending patent currently reviewed at the German Patent and Trade Mark Office; Other
non-financial interests from Elsevier, Wiley and Taylor & Francis online outside the
submitted work. K.L. received consultancy fees from SMB Laboratoires Brussels, MSD
and Gilead, travel support from Pfizer, speaker fees from FUJIFILM WAKO, Pfizer and
Gilead and a service fee from Thermo Fisher Scientific. M.H. received research funding
from Gilead Sciences, Astellas, Scynexis, F2G, MSD, and Pfizer, all outside the submitted
work. All other authors declare no conflict of interest for this study.